Huntington's drug trial extends for over four years to test Long-Term safety
NCT ID NCT06254482
Summary
This study is a long-term extension for people who completed an earlier trial of votoplam for Huntington's disease. It aims to monitor the safety and effects of the drug over an additional 54 months. All participants will receive the active drug, and researchers will track side effects and changes in key disease markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Clayton, 3168, Australia
-
Novartis Investigative Site
Westmead, 2145, Australia
-
Novartis Investigative Site
Innsbruck, 6020, Austria
-
Novartis Investigative Site
Ottawa, K1Y 4E9, Canada
-
Novartis Investigative Site
Angers, 49100, France
-
Novartis Investigative Site
Marseille, 13385, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Bologna, 40139, Italy
-
Novartis Investigative Site
Milan, 20133, Italy
-
Novartis Investigative Site
San Giovanni Rotondo, 71013, Italy
-
Novartis Investigative Site
Leiden, 2333 ZA, Netherlands
-
Novartis Investigative Site
Christchurch, 8011, New Zealand
-
Novartis Investigative Site
Barakaldo, 48903, Spain
-
Novartis Investigative Site
Barcelona, 8025, Spain
-
Novartis Investigative Site
Burgos, 90550, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Birmingham, B15 2FG, United Kingdom
-
Novartis Investigative Site
Cardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
London, WC1N 3BG, United Kingdom
-
Novartis Investigative Site
Manchester, M13 9WL, United Kingdom
Conditions
Explore the condition pages connected to this study.